DK1307486T3 - Somatostatinanaloger - Google Patents
SomatostatinanalogerInfo
- Publication number
- DK1307486T3 DK1307486T3 DK01969555T DK01969555T DK1307486T3 DK 1307486 T3 DK1307486 T3 DK 1307486T3 DK 01969555 T DK01969555 T DK 01969555T DK 01969555 T DK01969555 T DK 01969555T DK 1307486 T3 DK1307486 T3 DK 1307486T3
- Authority
- DK
- Denmark
- Prior art keywords
- somatostatin analogues
- somatostatin
- analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0018891.2A GB0018891D0 (en) | 2000-08-01 | 2000-08-01 | Organic compounds |
PCT/EP2001/008824 WO2002010192A2 (en) | 2000-08-01 | 2001-07-30 | Somatostatin analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1307486T3 true DK1307486T3 (da) | 2008-08-25 |
Family
ID=9896782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01969555T DK1307486T3 (da) | 2000-08-01 | 2001-07-30 | Somatostatinanaloger |
Country Status (36)
Country | Link |
---|---|
US (5) | US7473761B2 (hu) |
EP (1) | EP1307486B1 (hu) |
JP (1) | JP3829118B2 (hu) |
KR (2) | KR100799394B1 (hu) |
CN (1) | CN1267451C (hu) |
AR (1) | AR034132A1 (hu) |
AT (1) | ATE393782T1 (hu) |
AU (2) | AU2001289778B2 (hu) |
BE (1) | BE2012C026I2 (hu) |
BR (1) | BRPI0112859B8 (hu) |
CA (1) | CA2416293C (hu) |
CY (2) | CY1108547T1 (hu) |
CZ (1) | CZ302461B6 (hu) |
DE (1) | DE60133823T2 (hu) |
DK (1) | DK1307486T3 (hu) |
EC (1) | ECSP034456A (hu) |
ES (1) | ES2305104T3 (hu) |
FR (1) | FR12C0041I2 (hu) |
GB (1) | GB0018891D0 (hu) |
HK (1) | HK1057051A1 (hu) |
HU (1) | HU227812B1 (hu) |
IL (2) | IL153920A0 (hu) |
LU (1) | LU92024I2 (hu) |
MX (1) | MXPA03000991A (hu) |
MY (1) | MY138074A (hu) |
NO (2) | NO331093B1 (hu) |
NZ (1) | NZ523836A (hu) |
PE (1) | PE20020176A1 (hu) |
PL (1) | PL204161B1 (hu) |
PT (1) | PT1307486E (hu) |
RU (1) | RU2287533C2 (hu) |
SI (1) | SI1307486T1 (hu) |
SK (1) | SK287798B6 (hu) |
TW (1) | TWI282341B (hu) |
WO (1) | WO2002010192A2 (hu) |
ZA (1) | ZA200300406B (hu) |
Families Citing this family (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
AU2002359359A1 (en) | 2001-12-28 | 2003-07-24 | Somatocor Pharmaceuticals, Inc. | Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands |
RU2392265C2 (ru) * | 2002-12-12 | 2010-06-20 | Новартис Аг | Способ синтеза пептидов, содержащих подструктуру 4-гидроксипролина |
GB0229020D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic compounds |
GB0300095D0 (en) * | 2003-01-03 | 2003-02-05 | Novartis Ag | Organic compounds |
GB0314695D0 (en) * | 2003-06-24 | 2003-07-30 | Novartis Ag | Organic compounds |
PE20050285A1 (es) * | 2003-06-24 | 2005-06-09 | Novartis Ag | Composicion farmaceutica que comprende analogos ciclicos de somatostatina |
GB0318682D0 (en) * | 2003-08-08 | 2003-09-10 | Novartis Ag | Organic compounds |
EP1522311A1 (fr) | 2003-10-10 | 2005-04-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée |
MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
GB0412866D0 (en) * | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
GB0428151D0 (en) | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
GB0602639D0 (en) * | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
CA2655273A1 (en) * | 2006-06-08 | 2007-12-13 | Novartis Ag | Combination of somatostatin-analogs with dopamine- or growth hormone receptor antagonist |
US7697338B2 (en) * | 2006-11-16 | 2010-04-13 | Sandisk Corporation | Systems for controlled boosting in non-volatile memory soft programming |
CN101553728B (zh) * | 2006-11-28 | 2013-02-06 | 香港大学 | 颗粒体蛋白-上皮素前体(gep)抗体用于检测和抑制肝细胞癌(hcc)的用途 |
EP1941902A1 (en) * | 2007-01-02 | 2008-07-09 | Novartis AG | Use of Somatostatin analogs in cluster headache |
WO2008095063A1 (en) | 2007-01-31 | 2008-08-07 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
PE20090387A1 (es) | 2007-05-24 | 2009-04-28 | Novartis Ag | Formulacion de pasireotida |
WO2009009035A1 (en) * | 2007-07-06 | 2009-01-15 | Ipsen Pharma S.A.S. | Somatostatin analog and uses thereof |
GB0719818D0 (en) * | 2007-10-11 | 2007-11-21 | Asterion Ltd | Growth hormone fusion polypeptides |
US20100273719A1 (en) | 2007-11-28 | 2010-10-28 | Novartis Ag | Use of somatostatin analogs in meningioma |
ES2431573T3 (es) | 2007-12-03 | 2013-11-27 | Italfarmaco S.P.A. | Nuevos análogos no selectivos de somatostatina |
EP2067786A1 (en) | 2007-12-07 | 2009-06-10 | ITALFARMACO S.p.A. | Novel non selective analogs of somatostatin |
US20090325863A1 (en) * | 2008-06-13 | 2009-12-31 | Kleinberg David L | Somatostatin analogs and IGF-I inhibition for breast cancer prevention |
US9314508B2 (en) * | 2008-07-08 | 2016-04-19 | Novartis Ag | Use of somatostatin analogs in control of hypoglycemia |
EP2172189A1 (en) | 2008-10-01 | 2010-04-07 | Novartis AG | Pharmaceutical Compositions |
EP2213307A1 (en) | 2009-02-03 | 2010-08-04 | Novartis AG | Injectable depot formulations |
MX348705B (es) | 2008-09-17 | 2017-06-26 | Chiasma Inc | Composiciones farmacéuticas y métodos de administración relacionados. |
UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
US8629103B2 (en) | 2010-12-02 | 2014-01-14 | New York University | Treatment of non-proliferative cystic disease of the breast |
WO2012080260A1 (en) | 2010-12-13 | 2012-06-21 | Novartis Ag | Dimeric iap inhibitors |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
US20130035054A1 (en) * | 2011-07-14 | 2013-02-07 | Faceon Mobile | Phone with multi-portal access for display during incoming and outgoing call |
US8835123B2 (en) | 2011-08-02 | 2014-09-16 | New York University | Methods for detecting progenitor cells and uses thereof |
KR20140069235A (ko) | 2011-09-27 | 2014-06-09 | 노파르티스 아게 | 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
AU2012326026B2 (en) | 2011-10-18 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocyles |
AU2012348640B2 (en) | 2011-12-05 | 2016-07-21 | Camurus Ab | Robust controlled-release peptide formulations |
MX2014006736A (es) | 2011-12-05 | 2014-08-29 | Novartis Ag | Derivados de urea ciclicos como antagonistas de los receptores de androgeno. |
CN104302768A (zh) | 2012-01-09 | 2015-01-21 | 诺华股份有限公司 | 治疗β-联蛋白相关疾病的有机组合物 |
US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
CN112500466B (zh) | 2012-02-15 | 2022-05-03 | 艾瑞朗医疗公司 | 拟肽大环化合物 |
WO2013123267A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
SG11201407678YA (en) * | 2012-05-25 | 2014-12-30 | Camurus Ab | Somatostatin receptor agonist formulations |
TWI633887B (zh) | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及/或治療多囊性腎臟病之藥物 |
AU2013337388B2 (en) | 2012-11-01 | 2018-08-02 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
EP2922578B1 (en) | 2012-11-21 | 2018-12-12 | Serene, Llc | Tin-117m comprising somatostatin receptor binding compounds |
TR201806882T4 (tr) | 2013-02-19 | 2018-06-21 | Novartis Ag | Selektif östrojen reseptörü yıkıcıları olarak benzotiofen türevleri ve bunların bileşimleri. |
MX355945B (es) | 2013-03-14 | 2018-05-07 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
EP2970242B1 (en) | 2013-03-14 | 2017-09-06 | Novartis AG | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
WO2014147586A1 (en) | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
CN103467575B (zh) * | 2013-08-22 | 2016-03-02 | 深圳翰宇药业股份有限公司 | 一种帕西瑞肽的制备方法 |
CN103641894B (zh) * | 2013-12-06 | 2015-10-28 | 深圳翰宇药业股份有限公司 | 一种治疗库欣病的多肽药物的制备方法 |
WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
EP3082765B1 (en) | 2013-12-19 | 2018-08-01 | Novartis AG | Drug delivery systems |
CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
CN105899491B (zh) | 2014-01-17 | 2019-04-02 | 诺华股份有限公司 | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
JP2017516779A (ja) | 2014-05-28 | 2017-06-22 | アイデニクス・ファーマシューティカルズ・エルエルシー | 癌治療のためのヌクレオシド誘導体 |
BR112017005598A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
WO2016089830A1 (en) | 2014-12-05 | 2016-06-09 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
EP3226688B1 (en) | 2014-12-05 | 2020-07-01 | Merck Sharp & Dohme Corp. | Tricyclic compounds as inhibitors of mutant idh enzymes |
US10086000B2 (en) | 2014-12-05 | 2018-10-02 | Merck Sharp & Dohme Corp. | Tricyclic compounds as inhibitors of mutant IDH enzymes |
EP3229824A4 (en) | 2014-12-10 | 2018-07-11 | Chiasma Inc. | Oral octreotide administered in combination with other therapeutic agents |
US20210317161A1 (en) | 2014-12-19 | 2021-10-14 | Auro Peptides Ltd | A process for the preparation of pasireotide |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
WO2016126830A1 (en) | 2015-02-03 | 2016-08-11 | Chiasma Inc. | Method of treating diseases |
US10449211B2 (en) | 2015-03-10 | 2019-10-22 | Aduro Biotech, Inc. | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling |
KR20170129879A (ko) | 2015-03-20 | 2017-11-27 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
EP3280723B1 (en) * | 2015-04-08 | 2021-01-06 | Polyphor AG | Backbone-cyclized peptidomimetics |
US10815264B2 (en) | 2015-05-27 | 2020-10-27 | Southern Research Institute | Nucleotides for the treatment of cancer |
WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
EP3310774B1 (en) | 2015-06-19 | 2020-04-29 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
EP3310771B1 (en) | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
US10556924B2 (en) | 2015-06-22 | 2020-02-11 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the preparation of pasireotide |
GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
UA123701C2 (uk) | 2015-08-13 | 2021-05-19 | Мерк Шарп І Доум Корп. | Циклічні динуклеотидні сполуки як агоністи sting |
AU2016348391A1 (en) | 2015-11-03 | 2018-05-17 | Janssen Biotech, Inc. | Antibodies specifically binding TIM-3 and their uses |
EP3389783A4 (en) | 2015-12-15 | 2019-05-15 | Merck Sharp & Dohme Corp. | NOVEL COMPOUNDS THAN INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
WO2017191599A1 (en) | 2016-05-04 | 2017-11-09 | Genoscience Pharma | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
CN109415360B (zh) | 2016-06-14 | 2021-11-02 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
BR112019006816A8 (pt) | 2016-10-04 | 2023-02-07 | Merck Sharp & Dohme | Compostos de benzo[b]tiofeno como agonistas de sting, composição farmacêutica e uso dos mesmos |
US20190365788A1 (en) | 2016-11-21 | 2019-12-05 | Idenix Pharmaceuticals Llc | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases |
EP3573718B1 (en) | 2017-01-27 | 2022-06-01 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
ES2891326T3 (es) | 2017-01-27 | 2022-01-27 | Janssen Biotech Inc | Dinucleótidos cíclicos como agonistas de la STING |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
AU2018311966A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Benzo[b]thiophene sting agonists for cancer treatment |
JP2020529421A (ja) | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | がんの処置のためのPD−1アンタゴニストおよびベンゾ[b]チオフェンSTINGアゴニストの組み合わせ |
MA50245A (fr) | 2017-09-11 | 2020-07-22 | Krouzon Pharmaceuticals Inc | Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2 |
US11052065B2 (en) | 2017-09-27 | 2021-07-06 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist |
US11180497B2 (en) * | 2017-10-18 | 2021-11-23 | Angex Pharmaceutical, Inc. | Cyclic compounds as immunomodulating agents |
EP3703692A4 (en) | 2017-11-01 | 2021-04-28 | Merck Sharp & Dohme Corp. | NEW SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS |
CN111344287B (zh) | 2017-11-14 | 2023-12-19 | 默沙东有限责任公司 | 作为吲哚胺2,3-双加氧酶(ido)抑制剂的新型取代的联芳基化合物 |
EP3709986B1 (en) | 2017-11-14 | 2023-11-01 | Merck Sharp & Dohme LLC | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
WO2019118839A1 (en) | 2017-12-15 | 2019-06-20 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
WO2019195063A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
CA3095646A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
WO2019231870A1 (en) | 2018-05-31 | 2019-12-05 | Merck Sharp & Dohme Corp. | Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors |
US10596276B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
US10596278B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
KR20210060556A (ko) | 2018-09-18 | 2021-05-26 | 니캉 테라퓨틱스 인코포레이티드 | Src 호몰로지-2 포스파타아제 억제제로서의 3-치환된 헤테로아릴 유도체 |
WO2020068873A1 (en) | 2018-09-25 | 2020-04-02 | Black Diamond Therapeutics, Inc. | Tyrosine kinase inhibitor compositions, methods of making and methods of use |
BR112021005513A2 (pt) | 2018-09-25 | 2021-06-22 | Black Diamond Therapeutics, Inc. | derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos |
AU2019350592A1 (en) | 2018-09-29 | 2021-04-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
EP3873464A4 (en) | 2018-11-01 | 2022-06-08 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
EP3877366A4 (en) | 2018-11-06 | 2022-08-24 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
EP3886845A4 (en) | 2018-11-28 | 2022-08-10 | Merck Sharp & Dohme Corp. | NEW SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS |
EP3946324A4 (en) | 2019-04-04 | 2022-11-30 | Merck Sharp & Dohme LLC | HISTONE DEACETYLASE-3 INHIBITORS USEFUL FOR THE TREATMENT OF CANCER, INFLAMMATION, NEURODEGENERATIVE DISEASES AND DIABETES |
WO2020260547A1 (en) | 2019-06-27 | 2020-12-30 | Rigontec Gmbh | Design method for optimized rig-i ligands |
TW202120500A (zh) | 2019-08-02 | 2021-06-01 | 美商梅爾莎納醫療公司 | 干擾素基因刺激蛋白(sting)激動劑化合物及用途 |
CA3150701A1 (en) | 2019-08-15 | 2021-02-18 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
BR112022008074A2 (pt) | 2019-10-28 | 2022-07-12 | Shanghai Inst Materia Medica Cas | Composto de ácido oxocarboxílico heterocíclico de cinco membros e uso médico do mesmo |
EP4069683A1 (en) | 2019-12-06 | 2022-10-12 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
WO2021195206A1 (en) | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
AR122007A1 (es) | 2020-05-06 | 2022-08-03 | Merck Sharp & Dohme | Inhibidores de il4i1 y métodos de uso |
IL303661A (en) | 2020-12-22 | 2023-08-01 | Nikang Therapeutics Inc | COMPOUNDS FOR BREAKING CYCLIN-DEPENDENT KINASE 2 THROUGH THE UBIQUITIN PROTEOSOME PATHWAY |
US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
WO2022170052A1 (en) | 2021-02-05 | 2022-08-11 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof |
WO2022219412A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
EP4323350A1 (en) | 2021-04-14 | 2024-02-21 | Monte Rosa Therapeutics AG | Isoindolinone compounds |
WO2022227015A1 (en) | 2021-04-30 | 2022-11-03 | Merck Sharp & Dohme Corp. | Il4i1 inhibitors and methods of use |
CN117980310A (zh) | 2021-07-14 | 2024-05-03 | 尼坎治疗公司 | 作为kras抑制剂的亚烷基衍生物 |
WO2023192801A1 (en) | 2022-03-28 | 2023-10-05 | Nikang Therapeutics, Inc. | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors |
WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
WO2024047112A1 (en) * | 2022-08-30 | 2024-03-07 | Somtheranostics Sarl | Halogenated somatostatin analogs with multiple somatostatin receptor subtype selectivity |
WO2024102849A1 (en) | 2022-11-11 | 2024-05-16 | Nikang Therapeutics, Inc. | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3863008A (en) * | 1973-06-11 | 1975-01-28 | American Home Prod | Somatostatin as stimulant of luteinizing hormone secretion |
NZ195303A (en) | 1979-10-31 | 1984-10-19 | Merck & Co Inc | Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions |
US4292972A (en) * | 1980-07-09 | 1981-10-06 | E. R. Squibb & Sons, Inc. | Lyophilized hydrocolloio foam |
US4612386A (en) * | 1980-09-16 | 1986-09-16 | The Dow Chemical Company | Process for making esters |
US4505897A (en) * | 1983-04-18 | 1985-03-19 | The Administrators Of The Tulane Educational Fund | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith |
US4612366A (en) * | 1985-06-17 | 1986-09-16 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
CA2012115C (en) | 1989-03-15 | 2001-07-03 | Biomeasure, Inc. | Iodinated somatostatins |
KR0173119B1 (ko) | 1989-04-26 | 1999-02-01 | 닐 에이. 밴스로우 | 선형 소마토스타틴 유사체 |
US5620675A (en) | 1992-06-23 | 1997-04-15 | Diatech, Inc. | Radioactive peptides |
US5716596A (en) | 1992-06-23 | 1998-02-10 | Diatide, Inc. | Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses |
SG48977A1 (en) | 1993-06-23 | 1998-05-18 | Diatide Inc | Radiolabeled peptides |
ATE284413T1 (de) | 1993-08-09 | 2004-12-15 | Sod Conseils Rech Applic | Therapeutische peptid derivate |
US5770687A (en) | 1995-06-07 | 1998-06-23 | Peptor Limited | Comformationally constrained backbone cyclized somatostatin analogs |
MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
IT1277391B1 (it) | 1995-07-28 | 1997-11-10 | Romano Deghenghi | Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita |
ZA974147B (en) | 1996-05-14 | 1997-11-14 | Novo Nordisk As | Somatostatin agonists and antagonists. |
US6355613B1 (en) | 1996-07-31 | 2002-03-12 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
CA2246791A1 (en) | 1998-09-01 | 2000-03-01 | Alison Buchan | Treatment of endothelium with somatostatin analogues |
GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
-
2000
- 2000-08-01 GB GBGB0018891.2A patent/GB0018891D0/en not_active Ceased
-
2001
- 2001-07-26 PE PE2001000760A patent/PE20020176A1/es active IP Right Grant
- 2001-07-26 TW TW090118314A patent/TWI282341B/zh active
- 2001-07-30 IL IL15392001A patent/IL153920A0/xx unknown
- 2001-07-30 PL PL358718A patent/PL204161B1/pl unknown
- 2001-07-30 DK DK01969555T patent/DK1307486T3/da active
- 2001-07-30 CA CA2416293A patent/CA2416293C/en not_active Expired - Lifetime
- 2001-07-30 SK SK121-2003A patent/SK287798B6/sk not_active IP Right Cessation
- 2001-07-30 CZ CZ20030288A patent/CZ302461B6/cs unknown
- 2001-07-30 MY MYPI20013578A patent/MY138074A/en unknown
- 2001-07-30 US US10/343,288 patent/US7473761B2/en active Active
- 2001-07-30 WO PCT/EP2001/008824 patent/WO2002010192A2/en active IP Right Grant
- 2001-07-30 SI SI200130836T patent/SI1307486T1/sl unknown
- 2001-07-30 MX MXPA03000991A patent/MXPA03000991A/es active IP Right Grant
- 2001-07-30 AU AU2001289778A patent/AU2001289778B2/en active Active
- 2001-07-30 NZ NZ523836A patent/NZ523836A/en not_active IP Right Cessation
- 2001-07-30 AU AU8977801A patent/AU8977801A/xx active Pending
- 2001-07-30 JP JP2002515921A patent/JP3829118B2/ja not_active Expired - Lifetime
- 2001-07-30 PT PT01969555T patent/PT1307486E/pt unknown
- 2001-07-30 HU HU0300684A patent/HU227812B1/hu active Protection Beyond IP Right Term
- 2001-07-30 KR KR1020067005526A patent/KR100799394B1/ko active IP Right Grant
- 2001-07-30 EP EP01969555A patent/EP1307486B1/en not_active Expired - Lifetime
- 2001-07-30 CN CNB018136869A patent/CN1267451C/zh not_active Expired - Lifetime
- 2001-07-30 DE DE60133823T patent/DE60133823T2/de not_active Expired - Lifetime
- 2001-07-30 AR ARP010103642A patent/AR034132A1/es active IP Right Grant
- 2001-07-30 KR KR10-2003-7001435A patent/KR20030033008A/ko not_active Application Discontinuation
- 2001-07-30 BR BRPI0112859A patent/BRPI0112859B8/pt not_active IP Right Cessation
- 2001-07-30 AT AT01969555T patent/ATE393782T1/de active
- 2001-07-30 RU RU2003105817/04A patent/RU2287533C2/ru active Protection Beyond IP Right Term
- 2001-07-30 ES ES01969555T patent/ES2305104T3/es not_active Expired - Lifetime
-
2003
- 2003-01-13 IL IL153920A patent/IL153920A/en active Protection Beyond IP Right Term
- 2003-01-15 ZA ZA200300406A patent/ZA200300406B/xx unknown
- 2003-01-29 EC EC2003004456A patent/ECSP034456A/es unknown
- 2003-01-30 NO NO20030484A patent/NO331093B1/no not_active IP Right Cessation
- 2003-11-07 HK HK03108087A patent/HK1057051A1/xx not_active IP Right Cessation
-
2008
- 2008-07-29 CY CY20081100789T patent/CY1108547T1/el unknown
- 2008-11-05 US US12/265,135 patent/US7939625B2/en not_active Expired - Fee Related
-
2011
- 2011-03-16 US US13/048,935 patent/US9035021B2/en not_active Expired - Lifetime
- 2011-03-16 US US13/048,932 patent/US8822637B2/en not_active Expired - Lifetime
-
2012
- 2012-06-20 LU LU92024C patent/LU92024I2/fr unknown
- 2012-06-21 BE BE2012C026C patent/BE2012C026I2/fr unknown
- 2012-06-26 FR FR12C0041C patent/FR12C0041I2/fr active Active
- 2012-06-29 CY CY2012018C patent/CY2012018I2/el unknown
- 2012-06-29 NO NO2012012C patent/NO2012012I2/no not_active IP Right Cessation
-
2015
- 2015-04-08 US US14/681,226 patent/US20150218223A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2012018I2 (el) | Αναλογα σωματοστατινης | |
NO20032101D0 (no) | Apoliprotein analoger | |
ATE458877T1 (de) | Bodenbelag | |
DE60133295D1 (de) | Sulphoniumsalz-verbindung | |
DK1235777T3 (da) | Vitamin D-analoger | |
DE60119664D1 (de) | Kabelbaum | |
DK1401863T3 (da) | Kimære somatostatin-dopamin-analoge | |
DK1200399T3 (da) | Vitamin D3-analoger | |
NO20034497L (no) | Somatostatin agonister | |
DK1235824T3 (da) | D-vitaminanaloge forbindelser | |
DK1372688T3 (da) | Somatostatin-antagonister | |
NO20006320D0 (no) | Cykliske somatostatin-analoger | |
DE60122834D1 (de) | Torsions-Kipp-Komponente | |
DE60131345D1 (de) | Kommutatormotor | |
NO20024322L (no) | Sekvens | |
DE60134285D1 (de) | Förderer | |
DE50105875D1 (de) | Bauteil | |
DE60107637D1 (de) | Kabelbaum | |
GB0022877D0 (en) | Analogues | |
DE50107699D1 (de) | Bauelement | |
ATA12432000A (de) | Bauelement | |
FI4651U1 (fi) | Kaivo | |
FI20001398A (fi) | Kaivo | |
SE0003187D0 (sv) | Novel enkephalin analogues | |
UA3096S (uk) | Комбінований паркет |